Global Human Microbiome Market is poised to grow to USD 1318.72 Mn by 2030 with a CAGR of 31.08%

The report Global Human Microbiome Market by Product (Probiotics, Prebiotics, Food, Diagnostic Tests, Drugs), Application (Diagnostic, Therapeutic), and Region (North America, APAC, Europe, and LAMEA). With a market size of USD 88.06 Mn in 2020, the Global Human Microbiome Market Size will grow to USD 1318.72 Mn by 2030 with a CAGR of 31.08 %.

To know more about the report, Click on the link :-  https://www.strategicmarketresearch.com/market-report/human-microbiome-market

Key Factors that are expediting the Market growth

The high coincidence of disease, Government investment in R&D infrastructure and Healthcare facilities, mergers & collaborations, a rise in venture capital investments, a rise in the incidences of lifestyle-related diseases and autoimmune disorders in healthcare in the region. a growing number of drug development processes, and a growing number of research activities in this region

By Product, the Drugs category dominates the market.   \

The significant proportion of this segment can be attributed to the growing number of human microbiome-based medicinal products in clinical trials as well as increased funding for the development of microbiome-based pharmaceuticals.

By Application, the Diagnostic Centres dominated the market comprehensively. 

By Application, the Diagnostics sector is expected to show sheer Dominance.

The Diagnostics segment leads the market due to scientific and technological advancements in human genome mapping and the emergence of omics technologies.

THE REGION OF NORTH AMERICA SIGNIFICANTLY DOMINATED THE MARKET

The Dominance is because of the robust healthcare facilities and expanded investment in the development of sophisticated technology.

Because of increased awareness, more government initiatives, an increase in medical tourism, and increased R&D in the region, Asia-Pacific is expected to develop at the quickest rate.

IMPORTANT MARKET PLAYERS:

The significant players covered in the Global Human Microbiome Market include-- Yakult Honsha Co., AOBiome, Enterome Biosciences SA, Metabiomics Corp. (BioSpherex LLC), 

Microbiome Therapeutics LLC, Osel, Inc., Rebiotix, Inc., Second Genome, Seres Therapeutics, Synthetic Biologics, Inc., Vedanta Biosciences, 4D PharmaDu Pont De Nemours and Co.Merck & Co. Ferring Pharmaceuticals

Recent Developments

• In September 2021, Genetic Direction announced that it would process the assays in its CLIA- and CAP-certified laboratory, and PhenoBiome has launched a human gut microbiota assay.
• In June 2021, NovoSift, a breakthrough ex-vivo research and discovery platform, was established by NovoBiome, a drug development business, to examine the symbiotic link between the microbiota and the human intestine.
• On March 8, 2021, DuPont stated that it had reached a definitive agreement to buy Laird Performance Materials from Advent International, one of the world's leading private equity organisations.
• In June 2021, ENTEROME SA, a clinical-stage biotechnology firm, disclosed the accomplishments and capabilities of its unique product GeneMark-HM software, which has been featured in papers by NAR Genomics and Bioinformatics.
• In April 2018, Naked Biome, Inc., a microbiome-therapeutics start-up, successfully partnered with LEO Pharma to expedite the overall market growth.
• In April 2020, Gilead Sciences, Inc., and Second Genome, a leader in microbiome science, entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to five of Gilead's pipeline compounds in inflammation, fibrosis and other diseases, and to identify potential new targets for the treatment of inflammatory bowel disease (IBD).